Hope S. Rugo


Breast oncologist

Dr. Hope Rugo is a hematologist-oncologist who specializes in breast cancer treatment. She joined the UCSF Carol Franc Buck Breast Care Center after a decade at UCSF Medical Center, where she worked in bone marrow transplantation for a variety of diseases, including breast cancer.

Rugo is co-director of UCSF's breast cancer clinical trials program. She is the principal investigator for several clinical trials of potential new therapies. She is also an investigator with the Bay Area's SPORE (Specialized Programs of Research Excellence) on breast cancer. The National Cancer Institute established SPORE to foster collaborative, interdisciplinary cancer research.

  • Education

    University of Pennsylvania School of Medicine, 1984

  • Residencies

    UCSF Medical Center, Internal Medicine, 1987

  • Fellowships

    UCSF Medical Center, Hematology, 1990

    UCSF Medical Center, Oncology, 1995

  • Board Certifications

    Internal Medicine, American Board of Internal Medicine

    Medical Oncology, American Board of Internal Medicine

  • Academic Title


  • Languages



Clinics I work with

Breast Care Center

Berkeley Outpatient Center

3100 San Pablo Ave., Suite 430
Berkeley, CA 94702

My reviews


Overall Experience
294 Reviews
I feel very lucky Dr. Rugo is my Oncologist. She is wise and compassionate I have total confidence in her.
Explained things in a way that was easy to understand
292 Reviews
Did the doctor pay attention to your concerns
290 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
283 Reviews
Knew the important information about your medical history
290 Reviews
The provider showed respect for what you had to say
293 Reviews
The provider spent enough time with me
293 Reviews
Decorative Caduceus

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk H...

A Kaplan-Meier method will be used to estimate the survival curves and a stratified log-rank test will be used to compare the invasive disease-free survival (iDFS) of the two arms. A stratified Cox model will be used to estimate t...


Decorative Caduceus

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo...

The outcome measure of the study is IDFS, defined by the STEEP system as the first occurrence of the time from the date of randomization to the date of first invasive disease recurrence (local, regional or distant), the date of se...


Decorative Caduceus

The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanc...

Progression Free Survival is defined from the time from randomization to the first occurrence of disease progression as determined by the investigator using RECIST 1.1 or death from any cause, whichever occurs first.


Decorative Caduceus

A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positiv...


Decorative Caduceus

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients...

BORR is defined as the percentage of patients achieving complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and will be reported for each arm along with 95% two-side...


Decorative Caduceus

A Safety Study of SGN-LIV1A in Breast Cancer Patients

An AE is any untoward medical occurrence in a patient or clinical investigational subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment.


Decorative Caduceus

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small ...

Maximum Tolerated Dose (MTD) or recommended dose expansion (RDE) of DS-8201a (Part1) are based on the occurrence of DLTs.


Decorative Caduceus

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Ca...

The primary endpoint for the study is the median radiographic progression free survival (rPFS) in the Enobosarm Treatment Group compared to the Control Treatment Group. Progression will be defined based on RECIST 1.1.


Decorative Caduceus

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial C...

Number of Participants with DLTs and DLT-Equivalent Toxicities


Decorative Caduceus

Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast...

Will create a comprehensive biorepository that includes blood, archival tissue, fresh tissue, and linked molecular and clinical data from patients with recurrent and/or metastatic breast cancer.